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Introduction
As shown in Figure 1, a wide range of epidemiologic and
observational data suggest that oestrogens are associated
with the development of breast cancer [1,2]. With these data
as a background, it was quite surprising that recently
published data suggested that women taking postmeno-
pausal hormone therapy (MHT) with oestrogen alone for 5 to
9 years unexpectedly experienced a decrease in the risk for
breast cancer [3,4]. However, when taken for more than
20 years, the risk appeared to increase [5,6]. We call this the
‘oestrogen paradox’ to highlight the fact that short-term
oestrogen use decreases the risk for breast cancer whereas
long-term use increases it. A second component of the
oestrogen paradox is that high-dose oestrogen therapy in
postmenopausal women with breast cancer causes tumour
regression, whereas the anti-oestrogen tamoxifen is equally
effective in causing remissions in similar patient groups [7-9].
It is paradoxical then that both oestrogens and anti-oestro-
gens cause tumour regressions.
Short-term oestrogen use and breast cancer
risk
The initial publication of the Women’s Health Initiative (WHI)
[3] reported a 23% decrease in invasive breast cancer
incidence in patients taking oestrogen alone compared with
placebo, a finding which narrowly fell short of statistical
significance (hazard ratio [HR] 0.77, 95% confidence interval
[CI] 0.59 to 1.01). A recent exploratory analysis of updated
data from this study examined subgroups to determine
whether oestrogens might reduce the incidence of breast
cancer significantly in women falling into certain categories
[4]. Notably, this analysis reported a statistically significant
33% reduction in invasive breast cancer incidence in patients
who strictly adhered to their oestrogen therapy (HR 0.67,
95% CI 0.47 to 0.97). In addition, a 31% lower incidence of
localized breast cancer (HR 0.69, 95% CI 0.51 to 0.95) and
a 29% reduction in ductal cancers (HR 0.71, 95% CI 0.52 to
0.99) were reported in oestrogen users. The decreases in
breast cancer risk were limited to women who had not
previously used MHT [4]. In a concurrent report from the
Nurses Health Study [2], a significant 26% decrease in risk
for breast cancer was observed in obese women, and a
nonsignificant 10% decrease in all study participants, taking
oestrogen alone for 5 to 9 years. Other observational studies
reported a reduction in risk with oestrogen alone but of lesser
magnitude and not statistically significant. For example,
Schairer and colleagues [5] reported a 7% reduction in
breast cancer risk at 6 years in women receiving oestrogen
alone, and Lyytinen and coworkers [10] identified a similar
7% reduction. These combined results, although not conclu-
sive, are highly suggestive of a beneficial effect of oestrogen
in reducing breast cancer risk. However, this conclusion must
be considered provisional until rigorous confirmation in
additional studies is reported.
Long-term oestrogen use and breast cancer
risk
What are the data regarding use of oestrogen alone for more
than 20 years? The Nurses Health Study [2] also evaluated
women using oestrogen alone for more than 20 years and
found a statistically significant 41% increase in breast cancer
risk in women 50 years of age or older, and a 77% increase
in the subset of lean women. Earlier studies by Magnusson
[11] and Schairer [5] and their colleagues also identified
significantly increased breast cancer risks in women taking
oestrogen alone for more than 10 years (odds ratio 2.7) and
16 years (relative risk 1.6), respectively. The Million Women
Study [6] also reported a linear increase in breast cancer risk
over time in women receiving MHT with oestrogen alone over
a period of 10 years. In contrast to the other studies reported,
however, the Million Women Study found a nonsignificant
increased risk for breast cancer, even in women receiving this
therapy for less than 5 years.
High-dose oestrogens as breast cancer
treatment
A second component of the oestrogen paradox is that
women with hormone-dependent breast cancer respond to
high-dose oestrogens with objective tumour regressions. This
form of therapy was the mainstay of hormonal treatment of
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When compared in randomized trials with tamoxifen, high-
dose oestrogens were equally efficacious [7] and in one
study they were associated with significantly enhanced
survival [8] compared with an anti-oestrogen. Extensive
studies demonstrated that only specific subgroups of women
respond to high-dose oestrogen [9,12]. Premenopausal
women and those less than 1 year postmenopausal do not
respond at all. Women who had undergone menopause many
years earlier frequently experienced objective tumour regres-
sions; the longer the duration of the period after cessation of
menses, the greater the response rate. Only oestrogen
receptor (ER)-positive tumours regress in women receiving
high-dose oestrogens [12].
Possible mechanisms to explain the
oestrogen paradox
Our preclinical data demonstrate that long-term deprivation of
oestradiol causes this sex steroid to trigger cell death through
apoptosis (Figure 2a), whereas wild-type cells with a normal
oestrogen milieu exhibit reduced apoptosis (Figure 2b)
[13-21]. The postmenopausal women receiving MHT with
oestrogen alone may be considered to be in a state of long-
term oestradiol deprivation. Extensive review of autopsy
studies provides strong evidence that there is a reservoir of
undiagnosed breast cancer in postmenopausal women
(Table 1) [22,23]. The short-term reduction in breast cancer
in the patients with undiagnosed occult breast tumours may
be due to oestrogen-induced apoptosis of tumour cells.
Similarly, the effect of oestrogen in inducing tumour regres-
sions in patients with known breast cancer may reflect a
similar phenomenon. We suggest that the increased risk for
breast cancer results from long-term use of oestrogens alone
because the risk from MHT may occur via different
mechanisms [24,25]: the genotoxic effects of oestradiol
metabolites and the ER-mediated proliferative effects of
oestradiol. The following sections of this treatise will review
the evidence for each of these statements.
Occult pre-existing breast cancers in women
Over the past three decades at least eight studies have
assessed the frequency of occult malignant disease, primarily
ductal carcinoma in situ (DCIS), found at autopsy in women
with no history of breast cancer [22] (Table 1). The frequency
of occult DCIS varied considerably among these studies
(range 0% to 15%), most likely reflecting methodological
differences. Variation aside, approximately 5% of the 1,052
combined cases from these studies included occult DCIS
and 1% occult invasive breast cancers [22]. Based on these
findings, it is reasonable to assume that 5% to 10% of the
women entering the WHI and Nurse’s Health Study had
occult breast cancer when they were initially enrolled.
Evidence for oestradiol-induced apoptosis
Recent  in vitro studies from our laboratory showed that
hormone-dependent breast cancer cells deprived of
oestrogen in the long term undergo adaptive changes that
cause oestrogen to paradoxically stimulate apoptosis [13-15]
(Figure 2a). Whereas wild-type MCF7 cells respond to
oestradiol with a reduction in apoptosis, those deprived of
oestrogen in the long term exhibit an increase in programmed
cell death. Similarly, Jordan and collaborators [16-21]
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Figure 1
Hormonal risk factors associated with an increased risk of breast cancer and related to oestrogen exposure. For references supporting the validity
of this figure, see Santen [1]. E, oestrogen; E2, oestradiol; HRT, hormone replacement therapy; OOX, oophorectomy; P, progesterone. Reproduced
with permission from Santen RJ: Endocrine-responsive cancer. In Williams Textbook of Endocrinology. Edited by Larsen PR, Kronenberg HM,
Melmed S, Polonsky KS. Philadelphia, PA: WB Saunders Company; 2007:1763-1801. © Elsevier 2007. demonstrated that long-term tamoxifen exposure also results
in adaptation and development of oestrogen-induced apop-
tosis. Apoptotic mechanisms in adapted cells involve
upregulation of death receptor as well as mitochondrial
pathways. Specific molecular events include activation of the
Fas death receptor/Fas ligand complex, the release of
cytochrome C from the mitochondria, alterations in Bcl-2, and
downregulation of the anti-apoptotic factor nuclear factor-κ
[14,15,18].
Long-term oestradiol deprivation in the
Women’s Health Initiative and the Nurse’s
Health Study
At the time of enrolment, participants in the WHI trial were
63 years old on average and menopausal for more than
10 years [3]. Plasma oestradiol levels fall precipitously at
menopause from 50 to 600 pg/ml to levels of 5 to 10 pg/ml.
Even though breast tissue levels might not precisely reflect
plasma concentrations, one would still expect substantial
reduction in breast tissue levels and adaptation to this
reduction. If our hypothesis were correct, then exposure to
oestrogen therapy as MHT would induce apoptosis and
shrink or even eradicate the occult tumours, which would
reduce the detection of a cancer by mammography or
palpation over the next several years. This scenario could
explain the reduction in breast cancers diagnosed in the WHI
and Nurses Health Study in women receiving oestrogen
alone as MHT for 5 to 9 years [2,4]. This hypothesis would
also explain why women who had received MHT before
entering the WHI study did not experience a reduction in
breast cancer risk [4].
Long-term exposure to oestradiol
Why would oestrogen increase the risk for breast cancer
when it is given for more than 20 years? The commonly
accepted explanation for the carcinogenic effect of oestrogen
is that this sex steroid stimulates breast cancer proliferation
genes, increases the rate of breast cell divisions, and thereby
enhances the chances for development of mutations [25]. An
additional and more controversial mechanism suggests that
metabolites of oestradiol are directly genotoxic [24,25]
(Figure 3). Recent studies demonstrate that oestradiol is
converted to 4-OH-oestradiol in human breast tissue via the
cytochrome p450 1B1 enzyme, and it is then oxidized to
quinone metabolites. These metabolites are highly reactive
and covalently bind to adenine and guanine on DNA, resulting
in depurination, error-prone DNA repair, and point mutations
[24]. Other recent studies have shown that 4-OH-oestradiol
is directly mutagenic in cellular mutagenesis assays [26-29].
In addition, 4-OH-oestradiol can transform ER-negative
benign breast epithelial cells into serially transplantable
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Figure 2
Effect of oestradiol on apoptosis in wild type and long-term oestradiol-
deprived cells. (a) Long-term oestradiol deprived (LTED) MCF7 cells
respond to oestradiol (E2) with an increase in apoptosis, whereas 
(b) wild type MCF7 cells respond to the same dose of oestradiol with
a reduction in apoptosis. Reproduced with permission from Oxford
University Press from Song RX, Mor G, Naftolin F, McPherson RA,
Song J, Zhang Z, Yue W, Wang J, Santen RJ: Effect of long-term
estrogen deprivation on apoptotic responses of breast cancer cells to
17beta-estradiol. J Natl Cancer Inst 2001, 93:1714-1723.
Table 1
Occult breast cancers found at autopsy
Study Number %
1962 Ryan 200 0%
1973 Kramer 70 4.3%
1975 Wellings 67 1.9%
1984 Neilsen 77 14.3%
1985 Alpers 101 8.9%
1985 Bhathal 207 12.1%
1987 Bartow 221 0%
1988 Neilsen 109 14.7%
Total cases 1,052 5% DCIS and 1% IBC
Derived from the reports of Welch and coworkers [22] and Ryan [23].
DCIS, ductal carcinoma in situ; IBC, invasive breast cancer.carcinomas in immune deficient mice [28]. Finally, an ER
knockout model of breast cancer forms tumours in response
to increasing doses of exogenous oestradiol in previously
castrated animals [24,30]. These combined observations
suggest that directly genotoxic as well as ER-mediated
mechanisms may be responsible for the long-term carcino-
genic effects of oestradiol [24]. In time, the pro-carcinogenic
effects of oestradiol would outweigh the pro-apoptotic
effects.
Conclusion
A variety of data are congruent with our ‘oestrogen paradox’
hypothesis; however, additional confirmatory studies are
needed to prove this contention. Specifically needed are
more comprehensive autopsy studies to determine precisely
the magnitude of the reservoir of occult breast cancers and
their precursor lesions. The ability of highly sensitive imaging
strategies, such as digital mammography and magnetic
resonance imaging, should be evaluated for their abilities to
detect occult breast cancers in women initiating MHT. Direct
demonstration of oestrogen-induced apoptosis in occult
breast cancers in women will also be critical.
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